Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q7Z739
UPID:
YTHD3_HUMAN
Alternative names:
-
Alternative UPACC:
Q7Z739; B3KXL4; Q63Z37; Q659A3
Background:
YTH domain-containing family protein 3 plays a pivotal role in RNA metabolism, specifically recognizing and binding N6-methyladenosine (m6A)-containing RNAs. This modification is crucial for mRNA stability and processing. The protein is involved in the degradation of m6A-containing mRNAs, cellular differentiation, and acts as a negative regulator of type I interferon response. It also binds to circular RNAs and promotes the formation of phase-separated compartments like P-bodies.
Therapeutic significance:
Understanding the role of YTH domain-containing family protein 3 could open doors to potential therapeutic strategies.